Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients - Tabular View

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	No Study Results Posted


	Related Studies

Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients

This study has been completed.

Study NCT00005918. Last updated on October 1, 2007. Information provided by Bristol-Myers Squibb

This Tabular View shows the required WHO registration data elements as marked by ^†

Descriptive Information Fields
Brief Title ^†	Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients
Official Title ^†	The Safety and Antiviral Efficacy of Stavudine Extended Release Formulation as Compared to Stavudine Immediate Release Formulation, Each as Part of Potent Antiretroviral Combination Therapy
Brief Summary	The purpose of this study is to compare the safety and effectiveness of 2 forms of stavudine (d4T). One form is taken once a day (extended release) and the other form is taken twice a day (immediate release).
Detailed Description	Patients are randomized to receive blinded stavudine extended release (d4T ER) or immediate release (d4T IR) formulation. Randomization is balanced by screening HIV viral load of less than 30,000 copies/ml or at least 30,000 copies/ml and by site. Patients also receive open-label efavirenz (EFV) and lamivudine (3TC). Efficacy is evaluated over 48 weeks of the dosing period and safety is evaluated over the entire dosing period (56 weeks).
Study Phase	Phase III
Study Type ^†	Interventional
Study Design ^†	Treatment, Double-Blind, Safety Study
Primary Outcome Measure ^†
Secondary Outcome Measure ^†
Condition ^†	HIV Infections
Intervention ^†	Drug: Efavirenz Drug: Lamivudine Drug: Stavudine
MEDLINE PMIDs
Links	BMS Clinical Trials Disclosure For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm

Recruitment Information Fields
Recruitment Status ^†	Completed
Enrollment ^†	730
Start Date ^†	June 2000
Completion Date
Eligibility Criteria ^†	Inclusion Criteria Patients may be eligible for this study if they: Are at least 18 years old. Patients living in USA, Puerto Rico, Australia, Brazil, Singapore, and Thailand can be at least 12 years old (need consent of parent or guardian if under 18). Have a viral load of at least 2,000 copies/ml within 21 days of study entry. Have a CD4 count of at least 100 cells/mm3 within 21 days of study entry. Agree to use a barrier method of birth control (such as condoms) during the study. Are available for follow-up for at least 56 weeks. Exclusion Criteria Patients will not be eligible for this study if they: Are pregnant or breast-feeding. Have taken nonnucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs) for more than 30 days and within 14 days of study entry. Have a new opportunistic (HIV-related) infection or condition requiring treatment. Have acute (early) HIV infection. Have diarrhea (at least 6 loose stools/day for at least 7 days in a row) within 30 days prior to study entry. Abuse alcohol or drugs. Have active hepatitis within 30 days prior to study entry. Have a history of peripheral neuropathy (a condition affecting the nervous system). Cannot take medications by mouth. Are allergic to certain antiviral drugs. Need to take certain medications that should not be taken with EFV. Have certain other conditions or prior treatments that might affect the study.
Gender	Both
Ages	12 Years and older
Accepts Healthy Volunteers	No
Contacts ^††
Location Countries ^†	United States, Argentina, Australia, Belgium, Brazil, Canada, France, Israel, Italy, Mexico, Portugal, Puerto Rico, Russian Federation, Singapore, South Africa, Spain, Thailand

Administrative Information Fields
NCT ID ^†	NCT00005918
Organization ID	244F
Secondary IDs ^††	AI455-099
Study Sponsor ^†	Bristol-Myers Squibb
Collaborators ^††
Investigators ^†
Information Provided By	Bristol-Myers Squibb
Verification Date	October 2007
First Received Date ^†	June 15, 2000
Last Updated Date	October 1, 2007

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.